parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.07 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in salivary myoepithelial cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 35	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 4004

receipt 4012: USP31 in dopamine neurons, braak

power: full sample -0.56 (p 0.016, n 18), 95% CI -0.81 to -0.12. the interval excludes zero: something may be there, smaller than a half can see.
confounder: adjusted for sex: -0.57 (p 0.013, n 18). holds up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.59 (p 0.0099, n 18). not the mix.
skeptic: leave-one-out range -0.76 to -0.50, sign flips 0; without severely affected donors -0.56 (p 0.016, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for USP31 in dopamine neurons.

case closed: nothing better to follow up.

receipt 4011: USP31 in oligodendrocytes, braak

power: full sample +0.23 (p 0.365, n 18), 95% CI -0.27 to +0.63. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.13 (p 0.621, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.09 (p 0.722, n 18). could be the mix.
skeptic: leave-one-out range +0.11 to +0.40, sign flips 0; without severely affected donors +0.23 (p 0.365, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for USP31 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts